Argoudelis A D, Pyke T R, Sprague R W
J Antibiot (Tokyo). 1976 Aug;29(8):777-86. doi: 10.7164/antibiotics.29.777.
Rancinamycins I, II, III, and IV are secondary metabolites produced by Streptomyces lincolnensis in a sulfur-depleted culture medium. Rancinamycins I, and II, the main components of the mixture, show broad spectrum antibiotic activity in vitro. Subcutaneously injected or orally administered antibiotic afforded no protection for experimentally infected mice against lethal challenges of Staphylococcus aureus. Radioactive tracer studies failed to demonstrate that the rancinamycin were precursors in the biosynthesis of lincomycin.
兰卡霉素I、II、III和IV是林肯链霉菌在硫缺乏的培养基中产生的次级代谢产物。该混合物的主要成分兰卡霉素I和II在体外显示出广谱抗生素活性。皮下注射或口服该抗生素,对实验感染的小鼠抵御金黄色葡萄球菌的致命攻击没有提供保护作用。放射性示踪研究未能证明兰卡霉素是林可霉素生物合成中的前体。